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Abstract: Background: Cross-sectional studies have identified that the prevalence of neuropsychiatric
symptoms (NPS) in Parkinson’s disease (PD) ranges from 70–89%. However, there are few longitudinal
studies determining the impact of NPS on quality of life (QoL) in PD patients and their caregivers.
We seek to determine the progression of NPS in early PD. Methods: Newly diagnosed idiopathic
PD cases (n = 212) and age-matched controls (n = 99) were recruited into a longitudinal study. NPS
were assessed using the Neuropsychiatric Inventory with Caregiver Distress scale (NPI-D). Further
neuropsychological and clinical assessments were completed by participants, with reassessment at
18 and 36 months. Linear mixed-effects modelling determined factors associated with NPI-D and
QoL over 36 months. Results: Depression, anxiety, apathy and hallucinations were more frequent
in PD than controls at all time points (p < 0.05). Higher motor severity at baseline was associated
with worsening NPI-D scores over time (β = 0.1, p < 0.05), but not cognition. A higher NPI total
score was associated with poorer QoL at any time point (β = 0.3, p < 0.001), but not changed in QoL
scores. Conclusion: NPS are significantly associated with poorer QoL, even in early PD. Screening
for NPS from diagnosis may allow efficient delivery of better support and treatment to patients and
their families.
Keywords: neuropsychiatric symptoms; Parkinson’s disease; quality of life; non-motor
1. Introduction
Neuropsychiatric symptoms (NPS) are common in Parkinson’s disease (PD), with some studies
demonstrating a prevalence of 70–89% [1–3]. They can have a major impact on the lives of patients and
their families by contributing to morbidity, risk of institutionalisation [4], increased healthcare costs [5]
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and carer burden [6]. A recent study showed that NPS are missed in roughly half of consultations [7],
which may delay symptom recognition and management [8].
Depression is one of the most common NPS, occurring in almost 60% of PD patients [1]. Anxiety [9],
apathy and irritability are also common [3]. To date, there is a paucity of evidence on the burden of
NPS in PD and their progression over time, with the majority of research performed in cross-sectional
studies [1,3,10,11]. NPS are usually associated with the later stages of PD when they commonly occur
alongside a PD dementia (PDD); however, greater understanding of NPS in the earlier stages of disease
would be beneficial. We thus sought to identify the frequency and progression of NPS over time in
newly diagnosed PD cases compared to age-matched controls and to determine predictors of NPS
severity and QoL.
2. Materials and Methods
2.1. Participants
This study was conducted as part of the Incidence of Cognitive Impairment in Cohorts with
Longitudinal Evaluation—Parkinson’s disease (ICICLE-PD) study, which originally recruited PD
participants between June 2009 and December 2011 from the Newcastle upon Tyne region and
Cambridgeshire [12]. Participants were diagnosed by a movement disorder specialist and fulfilled UK
PD Brain Bank criteria [13]. Healthy controls recruited from the community in the North East were
matched with regards to age and sex. Exclusion criteria were Mini Mental State Examination (MMSE)
score < 24 or a diagnosis of dementia [14], atypical parkinsonian syndrome, vascular parkinsonism,
drug-induced parkinsonism, prevalent cases, and those without the capacity to consent.
This study was approved by the Newcastle and North Tyneside Research Ethics Committee and
performed in line with the Declaration of Helsinki. Participants provided written informed consent.
2.2. Assessments
Demographic data were collected, including age, sex, co-morbidities, medication, along with
years of education. Depression was assessed using the Geriatric Depression Scale-15 (GDS-15) [15].
Global cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) [16]. Disease
severity was assessed using the Movement Disorder Society revised Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS) parts II and III [17] and Hoehn and Yahr [18]. The Parkinson’s Disease
Questionnaire-39 (PDQ-39) [19] summary index (SI) was used as a measure of global QoL. This validated
tool comprises scores ranging from 0 (best QoL) to 100 (worst possible QoL score). PD participants
were assessed whilst “on” PD medication and their levodopa equivalent daily dose (LEDD) was
calculated [20].
Informants (partners, adult family members or friends of the participants) completed
the Neuropsychiatric Inventory Caregiver Distress (NPI-D) scale [21], a validated measure of
neuropsychiatric symptoms and carers’ level of distress. The NPI-D assesses the frequency and severity
of 12 neuropsychological symptoms and a composite score is obtained for each item, in addition to
a score for caregiver levels of distress. NPI total score ranges from 0–144, while caregiver distress
ranges from 0–60 (with higher scores indicating a greater disturbance of behaviour or levels of distress,
respectively). Participants were reassessed at 18 and 36 months.
2.3. Statistical Analyses
Statistical analyses were undertaken using SPSS (Version 24; SPSS, Inc., Chicago, IL, USA). The data
were tested for normality using the Kolmogorov–Smirnov test and visualised using histograms and
boxplots. Mann–Whitney U-tests and independent t-tests were performed to compare differences
between the two groups as appropriate. Chi-squared tests were performed for categorical data;
where a sample size was less than five, a Fisher’s exact test was used. McNemar’s test was used
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to assess changes in NPS frequency over time. A p-value of < 0.05 was considered significant in all
tests undertaken.
R software (Version 3.4.0; R Foundation for Statistical Computing, Vienna, Austria) and lme4
were used to perform a linear mixed-effects analysis of the relationship between clinical measures on
the NPS over 36 months. Due to the longitudinal nature of this study, there were some missing data.
This form of multilevel modelling is suitable for longitudinal data analysis due to its ability to handle
missing data [22], as it does not remove participant data list-wise. A random intercept model was
used, where the intercept varied at the participant and time level. Change in NPI total score over 36
months was first determined, with separate models for PDs and controls. Baseline age, sex, years of
education and LEDD score were entered into the model as fixed effects, as well as interactions of time
age (age × LEDD) and LEDD (Time × LEDD). Depression (GDS-15) was not included in the model
due to this domain being measured as part of the NPI-D scoring and was therefore not an independent
variable. A reduced model was produced by excluding non-significant predictors to which measures of
disease severity (MDS-UPDRS III) and cognition (MoCA) were then added. This method was repeated
to determine the predictors of carer distress. Fit of the models was assessed by likelihood ratio tests.
Linear mixed-effects models were used to determine whether the NPI total score was a significant,
independent predictor of QoL over 36 months. A random intercept model was used, where the
intercept varied at the participant and time level. Age, sex, years of education, LEDD, MoCA and
MDS-UPDRS III score were entered into the model as fixed effects, as well as interactions of time
with cognition (MoCA × Time), motor severity (Time ×MDS-UPDRS III) and LEDD (Time × LEDD).
As previously, depression (GDS-15) was not included in the model due to this domain also being
measured as part of the NPI. A reduced model was produced by excluding non-significant predictors
to which NPI total and interactions with time were then added. The Benjamini–Hochberg procedure
was used to correct for multiple comparisons in all analyses.
3. Results
At baseline, the average time from disease diagnosis in the PD group was 6.1 months. A percentage
of PD participants (76.4%; n = 162) had informants who completed the NPI-D at baseline and 72%
(n = 115) completed it at 36 months (Figure 1). In controls, 55% (n = 54) and 59% (n = 43) of the
informants completed the NPI-D at baseline and 36 months, respectively. There were no significant
differences in baseline demographics, NPI total score, caregiver distress score, QoL or global cognition
between those who were and those who were not included in this analysis (p > 0.05 for all; data not
shown).
Comparison of baseline characteristics for PD vs. controls (Table 1) showed that they were well
matched for age, gender and level of education (p > 0.05 for all). Consistently at each time point,
PD participants scored significantly lower for global cognition, and higher for depression, NPI total
score and NPI caregiver distress score compared to controls (p < 0.01 for all).
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Table 1. Comparison of demographic and clinical data in the Neuropsychiatric Inventory with Caregiver Distress scale (NPI-D) completers.
Baseline 18 Months 36 Months
PD n = 162 Control n = 54 T/z/χ2 p-value PD n = 144 Control n = 57 T/z/χ2 p-value PD n = 115 Control n = 42 T/z/χ2 p-value
Age (years) 66.2 (10.1) 67.5 (7.5) −1.0 0.335 † 68.3 (9.4) 68.6 (7.9) −0.2 0.830 † 69.3 (9.5) 70.6 (6.4) −1.0 0.313 †
Sex (Male) n (%) 104 (64.2) 30 (55.6) 1.3 0.257 * 97 (67.4) 30 (52.6) 3.8 0.051 * 79 (68.7) 23 (54.8) 2.6 0.105 *
Education (years) 12.5 (3.5) 13.0 (3.3) −1.1 0.261 12.8 (3.5) 13.1 (3.2) −0.9 0.373 12.7 (3.3) 12.8 (3.2) −0.3 0.801
Disease duration (months) 6.1 (5.4) - - - 24.1 (23.4) - - - 42.1 (41.4) - - -
GDS-15 3.1 (2.7) 1.0 (1.6) −6.0 <0.001 2.9 (2.7) 1.2 (2.0) −5.2 <0.001 3.1 (2.6) 1.2 (2.0) −5.0 <0.001
MoCA a 25.3 (3.4) 27.2 (2.2) −3.6 <0.001 26.1 (3.7) 27.6 (2.7) −2.9 0.004 25.6 (3.7) 27.4 (3.0) −3.0 0.002
NPI total score 6.7 (9.8) 1.9 (4.3) −4.5 <0.001 6.4 (9.5) 1.3 (3.3) −5.4 <0.001 7.2 (9.8) 3.3 (8.3) −4.3 <0.001
NPI-Caregiver distress score 3.3 (4.8) 0.9 (2.2) −4.4 <0.001 2.7 (4.0) 0.6 (1.9) −4.7 <0.001 3.8 (5.3) 1.5 (4.0) −4.0 <0.001
PDQ-39 19.0 (14.3) - - - 21.1 (16.3) - - - 22.3 (17.2) - - -
MDS-UPDRS-II 10.2 (5.9) - - - 11.8 (6.0) - - - 14.5 (7.6) - - -
MDS-UPDRS-III 27.7 (12.3) - - - 33.3 (12.1) - - - 35.2 (15.0) - - -
Hoehn and Yahr 1.9 (0.7) - - - 2.2 (0.5) - - - 2.1 (0.6) - - -
LEDD (mg/day) 190.4 (159.9) - - - 413.8 (214.3) - - - 518.2 (273.5) - - -
PDD n (%) 0 (0) - - - 8 (5.6) - - - 14 (12.2) - - -
All data presented are means (standard deviations) except where indicated. All data are non-parametric and test statistics are z-scores using Mann–Whitney U-test except where indicated.
† = independent t-test, * = chi-squared. Significant values indicated in bold. Abbreviations: GDS-15 = Geriatric Depression Scale-15, MoCA = Montreal Cognitive Assessment, NPI-D =
Neuropsychiatric Inventory with Carer Distress Scale, PDQ-39 = Parkinson’s Disease Questionnaire, MDS-UPDRS = Movement Disorder Society Unified Parkinson’s Disease Rating Scale,
LEDD = levodopa equivalent daily dose, PDD = PD dementia. a At baseline, n = 23 did not complete MoCA.
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3.1. Comparisons of NPS in PD VS. Controls
The frequency of NPS in PD and control participants was examined. Depression was the most
common symptom experienced by the PD cohort (35.8%, 32.6% and 36.5% at baseline, 18 and 36 months,
respectively). Anxiety, apathy and hallucinations were also reported frequently in PD participants
(Figure 2A). In controls (Figure 2B), the most common symptom experienced at each time point was
sleep disturbances (14.8% at baseline), but there were no significant changes for NPS over time (p > 0.05
for all). Comparison of NPS between baseline and 36-month assessments established that in PD
participants, hallucinations (p = 0.002) and disinhibition (p = 0.031) significantly increased in frequency
over time (Figure 2A), but no other significant differences were found (p > 0.05 for all). There were no
significant changes in NPS frequency over time in controls.Brain Sci. 2020, 10, x FOR PEER REVIEW 2 of 12 
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PD participants reported significantly higher frequencies of hallucinations (9.9% vs. 0%),
depression (35.8% vs. 11.1%), anxiety (29.6% vs. 9.3%) and apathy (24.7% vs. 5.6%) compared
to controls (p < 0.05 for all) at all time points. At 18 months, irritability and sleep disturbances were
higher in PD compared to controls (20.1% vs. 3.5% and 32.9% vs. 14.0%, respectively, p < 0.01). Appetite
changes were significantly higher in PD participants compared to controls at 18 months (20.1% vs.
3.5%) and 36 months (25.2% vs. 4.8%, p < 0.01 for both).
3.2. Factors Associated with NPS
Linear mixed-effects modelling was performed to determine baseline predictors of change in
NPI total score and carer distress total in PD and control participants over 36 months. No significant
predictors of NPI over time were identified using a data-driven approach, therefore age, sex and
time were used in all models as covariates (Table 2). In PD participants, increased baseline motor
severity was associated with increasing NPI total score over time (β = 0.1, p = 0.044), adjusting for
baseline age and sex; log-likelihood ratio comparing the fit of the basic model showed that including
the MDS-UPDRS III over time significantly improved the model (χ2 = 6.8, p = 0.009). No significant
associations were found between NPI total score and MoCA scores for PD or control participants.
Table 2. Baseline predictors of change in NPI total and NPI carer distress total using
mixed-effects modelling.
PD Control
β SE t-value p-value β SE t-value p-value
NPI total
Basic model
Sex (Male) 1.2 1.3 1.0 0.329 −0.8 1.0 −0.847 0.399
Age −0.1 0.1 −1.6 0.105 0.1 0.1 0.940 0.350
Time 0.4 0.4 0.9 0.390 0.6 0.5 1.193 0.235
Basic model +MDS-UPDRS III
MDS-UPDRS III 0.0 0.1 0.6 0.563
MDS-UPDRS III × Time 0.1 0.0 2.0 0.044
Basic model +MoCA
MoCA −0.4 0.2 −1.8 0.075 0.0 147.6 0.1 0.900
MoCA × Time −0.1 0.1 −0.7 0.457 −0.5 126.3 −1.9 0.057
NPI carer distress total
Basic model
Sex (Male) 0.8 0.6 1.3 0.206 0.1 0.5 0.124 0.901
Age 0.0 0.0 −0.3 0.791 0.0 0.0 0.525 0.601
Time 0.3 0.3 1.0 0.404 0.3 0.3 1.119 0.265
Basic model +MDS-UPDRS III
MDS-UPDRS III 0.0 0.0 0.1 0.957
MDS-UPDRS III × Time 0.1 0.0 3.1 0.002
Basic model +MoCA
MoCA −0.3 0.1 −2.7 0.007 0.0 147.8 −0.2 0.865
MoCA × Time 0.0 0.1 −0.8 0.432 −0.2 127.2 −1.9 0.065
Basic model includes age, sex and time as covariates. Figures highlighted in bold indicate significant results after
Benjamini–Hochberg procedure. Abbreviations: MoCA = Montreal Cognitive Assessment, MDS-UPDRS III =
Movement Disorder Society Unified Parkinson’s Disease Rating Scale part III.
Modelling carer distress scores found that increased baseline motor severity was significantly
associated with increasing NPI carer distress score over time (β= 0.1, p= 0.002, Table 2) and significantly
improved the fit of the model (χ2 = 5.0, p = 0.083). Higher baseline MoCA score was significantly
associated with lower NPI carer distress total (β = −0.3, p = 0.007), but not changed over time. No
significant associations were found in control participants.
3.3. Factors Associated with QoL
To determine whether NPS were significantly associated with QoL over time, predictors of change
in PDQ-39 scores over 36 months were determined. After excluding non-significant predictors, being
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female, lower years of education, younger age, increased dopaminergic medication (LEDD), increased
motor severity (MDS-UPDRS III) and decline in MoCA scores were significantly associated with
declining QoL (p < 0.05 for all, Table 3); only age, motor severity and declining cognition remained
significant after Benjamini–Hochberg correction for multiple comparisons.
Table 3. Predictors of change in quality of life (PDQ-39) using mixed-effects modelling.
Basic Model β SE t Value p-Value
Basic model
Sex (Female) −3.4 1.7 −2.1 0.041
Education (Years) −0.6 0.2 −2.5 0.012
Age −0.3 0.1 −3.9 <0.001
LEDD 0.0 0.0 3.1 0.002
MDS-UPDRS III 0.4 0.0 8.3 <0.001
Time (Assessment) 12.5 3.4 3.7 <0.001
MoCA −0.1 0.2 −0.4 0.654
MoCA × Time −0.5 0.1 −3.8 <0.001
Basic model + NPI Total
NPI Total 0.3 0.1 3.9 <0.001
NPI Total × Time 0.0 0.1 0.6 0.551
Basic model includes age, sex, years of education, MoCA, LEDD, MDS-UPDRS Part III, MoCA over time as covariates.
Figures highlighted in bold indicate significant results after Benjamini–Hochberg procedure. Abbreviations: PDQ-39
= Parkinson’s Disease Questionnaire, MoCA = Montreal Cognitive Assessment, LEDD = levodopa equivalent
daily dose, MDS-UPDRS III = Movement Disorder Society Unified Parkinson’s Disease Rating Scale part III, NPI =
Neuropsychiatric Inventory.
NPI total and NPI carer distress scores plus interactions with time were separately added to the
basic model. Increased NPI total score (β = 0.3, p < 0.001) but not its interaction with time (p > 0.05) was
associated with poorer QoL, suggesting the cross-sectional NPS burden was associated with poorer QoL
scores at any time point, but not associated with declining QoL. Similarly, increased NPI carer distress
score but not its interaction with time was associated with poorer QoL. This suggests that cross-sectional
carer distress due to NPS was associated with poorer QoL scores at any time point, but not associated
with declining QoL. These associations remained significant after Benjamini–Hochberg correction.
4. Discussion
To our knowledge, this is the first longitudinal study to explore the natural history of NPS over
time in newly diagnosed PD. We demonstrated that such patients experienced increased NPS burden
and caregiver distress compared to controls over the 36-month study period. In PD, increased NPS
was associated with worsening motor severity over 36 months and contributed to poorer QoL, but was
not associated with changes in cognition. Depression was the most common symptom experienced
in newly diagnosed PD patients, with anxiety, apathy and hallucinations also frequently reported.
Hallucinations and disinhibition significantly increased over time.
Similar findings have been reported by Weintraub et al. [11], where depression, apathy and anxiety
were also higher in PD patients compared to controls in a larger sample of newly diagnosed PD subjects
(n = 423) and controls (n = 196). We found hallucinations were also common and increased in frequency
along with agitation over time. This is consistent with findings reported by Williams et al. [23] and
Holroyd et al. [24], who found that up to half of participants experienced visual hallucinations. This is
an important finding since hallucinations are associated with greater severity of disease [25] and the
development of PDD [26]. This can have a negative impact on carers and increases risk of care home
placement [27].
Consistent with our findings, carer distress in NPS has been reportedly higher in PD compared
to controls in previous research [28]. Almost half of the carers of newly diagnosed PD participants
reported distress using the NPI-D assessment compared to 16% of controls, with over 25% of PD carers
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experiencing moderate to severe distress at baseline. In the present study, we have shown carers’
distress scores of PD participants were almost four times that of control informants even at diagnosis.
This may be explained by increasing responsibilities and strain on the relationship affecting carers’
QoL [1,28–30].
Over the 36-month study period, increased baseline motor severity was associated with an
increased NPI total score and increased carer distress. This is in keeping with current knowledge that
NPS are more frequently seen in the later stages of PD and hence more advanced motor stages of
the condition [1]. Contrary to our hypotheses, the MoCA was not significantly associated with the
NPI total score. Previous studies have shown associations between global cognition and NPS burden.
Aarsland et al. [1] showed that patients with a lower MMSE were likely to have greater NPS, supported
by further research by Leroi et al. [31]. Compared to previous studies, participants in our cohort had
less advanced disease; participants’ had a mean PD duration of 6 months at baseline and were largely
Hoehn and Yahr stage 1 or 2.
Similar to previous prevalent cohort studies [28–33], we found that NPS were a significant
contributor to poorer quality of life in PD participants. The significance of our work is that this is
evident even in newly diagnosed participants. Previous research has shown depression, hallucinations
and anxiety are associated with poorer QoL [34]. However, further research is needed to fully
understand and appreciate the role of other NPS and their effect on the QoL of patients [35]. It has
been reported that these NPS are under-recognised [36] and thus undertreated; our results highlight
the importance of screening for these symptoms in the early stages of disease which consequently may
lead to improvements in patient’s QoL and reduce caregiver distress [28].
The strengths of this study are the use of data from a large representative community-based
population of newly diagnosed patients with idiopathic PD. Additionally, the use of a control group
allowed for comparisons with normal ageing. Our results draw attention to the significant differences
between the two groups; this is an important finding as it highlights the increased prevalence of NPS
in PD compared to the healthy population. This study replicates and extends the findings of previous
cross-sectional studies [1,3,11]. The progression of NPS over time in incident PD participants compared
to controls in the current literature has not been studied longitudinally.
The limitations of our study include the fact that the participants were not drug naïve; therefore it
was not possible to determine whether medication had an influence on NPS, although our findings
represent patients seen in normal routine clinical practice. The NPI-D tool [21] is also subject to
inter-rater variability, although we attempted to minimise this by using a trained researcher to ask the
informant about their NPS. Moreover, participants at baseline had an average duration of disease of 6
months and therefore some NPS may be mild and hence underreported. We note that GDS-15, NPI
and NPI-D scores were relatively low across the cohort at baseline, and thus potentially our patients
were not very burdened by these symptoms. Due to the longitudinal nature of the study, participant
drop-out was inevitable and it is possible that those who withdrew may have been experiencing greater
NPS and so we may have underestimated their frequency. We acknowledge that, as in any longitudinal
study, there was a degree of attrition, and although there was a lack of baseline differences in NPS
between those who did and did not drop out, this may not necessarily reflect the trajectory and rate of
decline over time. This may be particularly true for tests with a high ceiling or floor effect, such as
the MoCA and GDS-15, respectively, which thus may have introduced bias. However, we used linear
mixed-effects modelling in our analysis, which has the advantage that it is able to handle missing data
and so does not remove participant data list-wise, which helps to mediate some of this bias.
5. Conclusions
Neuropsychiatric symptoms and caregiver distress were greater in newly diagnosed PD
participants compared to controls and were significantly associated with poorer QoL. These findings
can be utilised in clinical practice as they highlight the importance of screening for NPS early in the
course of the disease. Results from this study identified the most prevalent NPS in early PD, which
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were depression, anxiety, apathy and hallucinations. A major unmet research need is to find effective
treatments for these symptoms, thus helping to alleviate distress amongst patients and their carers.
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